Open Nav

Please submit your session questions in advance at http://bit.ly/BIOCEO19question

Galimedix Therapeutics

  • Andrew Pearlman, Galimedix Therapeutics

Galimedix is a Phase 2 US/Israel clinical stage ophthalmic biopharma company developing truly novel and transformative treatments based on a novel mechanism of action directed to the common cause of many neurodegenerative diseases: toxic oligomers of amyloid beta. Lead product, GAL-101, is an eye drop for treatment to slow progression of dry macular degeneration of the retina, and glaucoma: two of the leading causes of blindness. Led by a highly experienced biopharma team including many ex-Pharma executives, Galimedix has an exclusive worldwide license from Tel Aviv University and German-based Merz Pharmaceuticals, where the compound was developed for seven years through Phase I. A next generation, potentially superior compound, GAL-201, is in preclinical development for oral administration, with the potential to treat CNS diseases such as Alzheimer’s. The Board of Directors and scientific advisors include many leading names in the field of glaucoma and retinal disease.

  • Date:Tuesday, February 12
  • Time:11:00 AM - 11:15 AM
  • Room:Chelsea
  • Location:7th Floor
  • Session Type:Company Presentation
  • Submission ID:23555
  • Company Presentation - Presentation Type:Privately Funded Company
  • Goal for Presentation:Fundraising and business development
  • Company Website:www.galimedix.com
  • Company HQ City:Kensington
  • Company HQ State:Maryland
  • Company HQ Country:United States
  • Total Amount Raised to Date, in All Rounds:$42,000,000
  • Size of Last Investment Round:$2,000,000
  • Previous and Current Investors:Merz Pharmaceutical, InFocus Fund, Rimonci International Specialized Fund
  • CEO/Top Company Official:Andrew Pearlman
  • Year Founded:2018
  • Main Therapeutic Focus:Ophthalmology
  • Lead Product in Development:GAL-101 (spin-off)
  • Development Phase of Primary Product:Phase II
  • Additional Information/Comments:Following initial funding round led by two specialty Ophthalmic funds, Galimedix in-licensed the exclusive worldwide rights to the spin-off technology, which has already enjoyed more than $40,000,000 and 7 years of development at the highest pharma industry level. Having successfully completed Phase 1 safety in 70 subjects and pre-IND for Phase 2b, the company plans to submit IND and launch two Phase 2 studies during H2 2019, months after completing its major funding round. GAL-101 and 201 are small molecules, designed to prevent the formation of all forms of toxic amyloid beta oligomers: an underlying cause of glaucoma and dry AMD, with the potential to delay/halt disease progression and improve visual function. The planned route of administration is patient friendly eye drops, which showed excellent delivery into the retinas of primate animal models. If eye drops show efficacy in patients, it would be a major compliance advantage for the elderly over ocular injections.
Speakers
Andrew Pearlman
Galimedix Therapeutics
Back